Justia Antitrust & Trade Regulation Opinion Summaries

MCEP, an acute care, for-profit hospital owned by 60 physicians and one corporate shareholder, opened in 2006. By 2009, MCEP’s existence as a physician-owned enterprise ended when it sold an ownership interest to Kettering Health Network, a competitor in the Dayton healthcare market. MCEP alleges that it failed because of the anticompetitive actions of Premier, a dominant healthcare network in the Dayton area. MCEP alleges that Premier contracted with area physicians and payers (insurers and managed-care plan providers) on the condition that they did not do business with MCEP. MCEP claims that Premier engaged in a conspiracy so devoid of benefit to the market as to be per se illegal under the Sherman Act, 15 U.S.C. 1. The Sixth Circuit affirmed summary judgment in favor of the defendants. To be per se illegal, a defendant’s conduct has to be so obviously anticompetitive that it has no plausibly procompetitive features. Premier’s contracts with payers and physicians had plausibly procompetitive features. It is plausible that panel limitations, which prohibited referrals to MCEP, lower the cost of defendants’ services and improve “cost effectiveness and efficiencies in the delivery of health care services.” View "Medical Center at Elizabeth Place, LLC v. Atrium Health System" on Justia Law

The Second Circuit affirmed the district court's dismissal of LBE's action alleging claims under the Sherman Act and the Racketeer Influenced and Corrupt Organizations Act (RICO). LBE alleged that Barbri and law schools entered into agreements whereby Barbri donates money to the schools, bribes their administrators, and hires their faculty to teach bar review courses. LBE further alleged that, in exchange, the law school gives Barbri direct access to promote and sell its products on campus.The court adopted the district court's well-reasoned and thorough analysis of LBE's allegations and held that the district court properly dismissed the complaint under Federal Rule of Civil Procedure 12(b)(6) for failure to state a plausible claim of relief. The district court concluded that internal contradictions and conclusory assertions in the complaint did not plausibly support LBE's claim that Barbri and the law schools conspired to enable Barbri to gain a monopoly. View "LLM Bar Exam, LLC v. Barbri, Inc." on Justia Law

The Supreme Court affirmed the judgment of the trial court granting a company using registered trade names (Plaintiff) a permanent injunction, statutory damages, and attorney fees against a corporation using a similar name (Defendant), holding that that Plaintiff was entitled to relief, and this relief is unaffected by the Court's determination that Plaintiff proved only two of its three causes of action.Specifically, the Court held (1) the denial of Defendant's motion to dismiss under Neb. Rev. Stat. 6-1112(b)(6) is moot; (2) Defendant's argument that the trial court erred in denying its motion under section 6-1112 lacked merit; (3) Plaintiff met its burden of proof regarding its claims for trade name infringement and deceptive trade practices, but it did not establish tortious interference with a business relationship or expectancy; and (4) the relief ultimately granted was supported by Plaintiff's claims for trade name infringement and deceptive trade practices. View "Denali Real Estate, LLC v. Denali Custom Builders, Inc." on Justia Law

The Supreme Court affirmed in part the district court's denial of Defendants’ request for attorney fees and dismissed in part Defendants’ appeal from orders vacating summary judgment in favor of Defendants and overruling Defendants’ subsequent motion for summary judgment, holding that Defendants did not qualify as prevailing parties and that this Court lacked jurisdiction to review the summary judgment orders.The State brought claims against Defendants under Nebraska’s Consumer Protection Act, Neb. Rev. Sat. 59-1601 et seq., and the Uniform Deceptive Trade Practices Act, Neb. Rev. Stat. 87-301 et seq. The district court entered summary judgment in favor of Defendants and then later vacated its order of summary judgment. Defendants moved again for summary judgment, which the district court denied. After years of litigation, the State voluntarily dismissed the claims. The district court denied Defendants’ request for attorney fees, finding that the State’s voluntary dismissal did not make Defendants prevailing parties or purposes of section 59-1608(1). The Supreme Court affirmed in part and dismissed in part, holding that this Court lacked jurisdiction to review Defendants’ claim that the district court’s summary judgment orders were erroneous and that the district court did not err in denying Defendants’ motion for attorney fees. View "State ex rel. Peterson v. Creative Community Promotions, LLC" on Justia Law

Richmond issued its first medical marijuana collective permit to RCCC. Three other permits were later issued. The ordinance was amended to reduce the number of dispensary permits from six to three; if a permitted dispensary did not open within six months after the issuance of a permit, the permit would expire. RCCC lost its permit. RCCC filed an antitrust complaint under the Cartwright Act, alleging that the other dispensaries paid for community opposition to RCCC’s applications and also purchased a favorably zoned property. Defendants filed a joint anti-SLAPP (strategic lawsuit against public participation) motion to strike (Code of Civil Procedure 425.16), which was granted as to allegations related to protected activity--statements made before the city council and defendants’ actions in opposing RCCC’s application. Allegations related to the property purchase were not stricken. Some defendants sought attorney fees. The trial judge determined that “defendants prevailed on their” anti-SLAPP motions and awarded 7 Stars $23,120 plus costs of $688.12. The court of appeal affirmed. There is no conflict between the anti-SLAPP statute, which permits an award of attorneys’ fees to a defendant and the Cartwright Act, which permits only a plaintiff to be “awarded a reasonable attorneys’ fee together with the costs of the suit” (Bus. & Prof. Code 16750(a)). View "Richmond Compassionate Care Collective v. 7 Stars Holistic Foundation" on Justia Law

In this action brought by the administrators of the estates of nine people killed in the massacre at Sandy Hook Elementary School, the Supreme Court held that the trial court properly determined that, although the trial court properly struck most of Plaintiffs’ claims against various manufacturers, distributors and sellers of the Bushmaster XM15-E2S semiautomatic rifle, the Protection of Lawful Commerce in Arms Act (PLCAA), 15 U.S.C. 7901 through 7903, did not bar Plaintiffs’ claims that Defendants violated the Connecticut Unfair Trade Practices Act (CUPTA), Conn. Gen. Stat. 42-110a et seq., by marketing the firearm to civilians for criminal purposes and that those wrongful marketing tactics contributed to the massacre.Adam Lanza carried out the massacre using a XM15-E2S. The Supreme Court affirmed the trial court’s judgment that most of Plaintiffs’ claims were precluded by established Connecticut law and/or PLCAA. However, as to Plaintiffs’ claims that Defendants knowingly marketed, advertised, and promoted the XM15-E2S for civilians to use to carry out offensive, military style combat missions, the Supreme Court held that Plaintiffs pleaded allegations sufficient to survive a motion to strike because (1) PLCAA does not bar Plaintiffs’ wrongful marketing claims; and (2) to the extent that it prohibits the unethical advertising of dangerous products for illegal purposes, CUTPA qualifies as a predicate statute. View "Soto v. Bushmaster Firearms International, LLC" on Justia Law

The Body Shops filed suit alleging that defendant insurance companies colluded to lower repair prices by improperly pressuring the shops to lower prices and by threatening to boycott those who did not comply. The Body Shops claimed a per se price-fixing conspiracy and a per se conspiracy to boycott, as well as state law claims.The Eleventh Circuit affirmed the district court's dismissal of all of the Body Shop's federal antitrust and state law claims except the tortious interference claims. Although the court held that the unjust enrichment and quantum meruit claims of the Body Shops were wholly without merit, the court vacated the district court's judgment as to the tortious interference claims because the court was not persuaded by the district court's grounds for concluding that the allegations of tortious interference in each of these five cases violated the group pleading doctrine, i.e., failed to give fair notice to each defendant of the claim being made against it. The court remanded for further proceedings. View "Quality Auto Painting Center of Roselle, Inc. v. State Farm Indemnity Co." on Justia Law

The Fifth Circuit dismissed a petition for review of an FTC order based on lack of jurisdiction. The court held that the FTC's order denying the Board's motion to dismiss and granting the FTC's motion for partial summary decision was not a cease and desist order and thus the Federal Trade Commission Act did not expressly authorize the court to exercise jurisdiction in this case. The court also held that the language in the Act could not be interpreted to allow appellate review of collateral orders. View "Louisiana Real Estate Appraisers Board v. FTC" on Justia Law

In an action filed by the government to enjoin the vertical merger between AT&T and Time Warner under Section 7 of the Clayton Act, the DC Circuit affirmed the district court's denial of the government's request for a permanent injunction. At issue on appeal was the district court's findings on its increased leverage theory whereby costs for Turner Broadcasting System's content would increase after the merger, principally through threats of long-term "blackouts" during affiliate negotiations.The court held that the government failed to clear the first hurdle in meeting its burden of showing that the proposed merger was likely to increase Turner Broadcasting's bargaining leverage. Furthermore, the government's objections that the district court misunderstood and misapplied economic principles and clearly erred in rejecting the quantitative model were unpersuasive. In this case, the government offered no comparable analysis of data for prior vertical mergers in the industry that showed "no statistically significant effect on content prices" as defendants had. Additionally, the government's expert opinion and modeling predicting such increases failed to take into account Turner Broadcasting System's post-litigation irrevocable offers of no-blackout arbitration agreements, which a government expert acknowledged would require a new model. The court also held that the evidence indicated that the industry had become dynamic in recent years with the emergence of distributors of only on-demand content, such as Netflix and Hulu. View "United States v. AT&T, Inc." on Justia Law

Shire manufactured and marketed the lucrative drug Vancocin, which is used to treat a life-threatening gastrointestinal infection. After Shire learned that manufacturers were considering making generic equivalents to Vancocin, it inundated the Food and Drug Administration (FDA) with allegedly meritless filings to delay approval of those generics. The FDA eventually rejected Shire’s filings and approved generic equivalents to Vancocin. The filings resulted in a high cost to consumers. Shire had delayed generic entry for years and reaped hundreds of millions of dollars in profits. Nearly five years later, after Shire had divested itself of Vancocin, the Federal Trade Commission (FTC) filed suit against Shire under Section 13(b) of the Federal Trade Commission Act, 15 U.S.C. 53(b), seeking a permanent injunction and restitution, and alleging that Shire’s petitioning was an unfair method of competition. The district court dismissed, finding that the FTC’s allegations of long-past petitioning activity failed to satisfy Section 13(b)’s requirement that Shire “is violating” or “is about to violate” the law. The Third Circuit affirmed, rejecting “the FTC’s invitation to stretch Section 13(b) beyond its clear text.” The FTC admits that Shire is not currently violating the law and did not allege that Shire is about to violate the law. View "Federal Trade Commission v. Shire ViroPharma Inc" on Justia Law